Literature DB >> 36199905

The effectiveness of erysipelas prophylaxis depends on the cumulative dose of benzathine penicillin G.

Agnieszka Bednarska1,2, Iwona Sosińska-Bryła2, Paweł Grąbczewski2, Regina Podlasin2, Marcin Paciorek1,2, Dominik Bursa1,2, Małgorzata Hackiewicz2, Michał Makowiecki2, Andrzej Horban1,2.   

Abstract

Erysipelas is an acute infection due to S. pyogenes and is characterized by a high risk of relapses. The number of patients suffering from one or more recurrences varied depending on the study and accounted for between 16% and 47% of the total number of those affected. Antibiotic prophylaxis with the use of penicillin can reduce the risk of recurrence by 47%. A number of 873 patients with erysipelas treated at the Hospital for Infectious Diseases in Warsaw from 2010 to 2018 was enrolled in the study. Benzathine-penicillin G was given intramuscularly at a dose of 1.2 MU or 2.4 MU or 3.6 MU. The earliest moment that prophylactic treatment was administered was the first episode of erysipelas recurrence. The decision to administer the antibiotic and the dose to use was discretionally made by the examining physician. Altogether 104 (11.9%) persons experienced at least one episode of erysipelas recurrence during the study period. A total of 2976 doses of benzathine- penicillin G (BP) were administered. The most common dose was that of 2.4 MU (2380, 80%). The dose of 1.2 MU was given 567 times (19%). The highest dose, i.e. 3.6 MU, was administered to only 5 patients (8 applications, 0.2%). No effect was shown by either the number of benzathine- penicillin G administered doses (p=0.07) or the median dose (p=0.65), whereas patients without relapse received a statistically higher cumulative dose of the antibiotic (p=0.047). Age was a risk factor of recurrence only in the group of diabetic patients (p=0.03). Benzathine penicillin G given in an appropriate cumulative dose is effective in preventing erysipelas recurrence. ©Copyright: the Author(s).

Entities:  

Keywords:  Benzathine penicillin G; Cumulative dose; Erysipelas; Recurrence

Year:  2022        PMID: 36199905      PMCID: PMC9527694          DOI: 10.4081/dr.2022.9429

Source DB:  PubMed          Journal:  Dermatol Reports        ISSN: 2036-7392


  16 in total

1.  Recurrent erysipelas despite antibiotic prophylaxis: an analysis from case studies.

Authors:  J B Koster; B J Kullberg; J W M van der Meer
Journal:  Neth J Med       Date:  2007-03       Impact factor: 1.422

2.  Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment.

Authors:  Maciej Piotr Chlebicki; Choon Chiat Oh
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

3.  The experience of intramuscular benzathine penicillin for prophylaxis of recurrent cellulitis: A cohort study.

Authors:  Hsien-Meng Chen; Yu-Lin Li; Yuag-Meng Liu; Chun-Eng Liu; Yu-Ren Cheng; Chang-Hua Chen; Ing-Moi Hii; Chih-Yen Chang
Journal:  J Microbiol Immunol Infect       Date:  2015-09-09       Impact factor: 4.399

Review 4.  Antibiotic prophylaxis for preventing recurrent cellulitis: a systematic review and meta-analysis.

Authors:  Choon Chiat Oh; Henry Chung Hung Ko; Haur Yueh Lee; Nasia Safdar; Dennis G Maki; Maciej Piotr Chlebicki
Journal:  J Infect       Date:  2014-02-24       Impact factor: 6.072

5.  Recurrent erysipelas: 47 cases.

Authors:  S Leclerc; A Teixeira; E Mahé; V Descamps; B Crickx; O Chosidow
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

6.  Benzathine penicillin G once-every-3-week prophylaxis for recurrent erysipelas a retrospective study of 132 patients.

Authors:  Filip Rob; Jana Hercogová
Journal:  J Dermatolog Treat       Date:  2017-05-30       Impact factor: 3.359

7.  Epidemiology and comorbidity of erysipelas in primary care.

Authors:  Stefaan Bartholomeeusen; Jan Vandenbroucke; Carla Truyers; Frank Buntinx
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

8.  Penicillin to prevent recurrent leg cellulitis.

Authors:  Kim S Thomas; Angela M Crook; Andrew J Nunn; Katharine A Foster; James M Mason; Joanne R Chalmers; Ibrahim S Nasr; Richard J Brindle; John English; Sarah K Meredith; Nicholas J Reynolds; David de Berker; Peter S Mortimer; Hywel C Williams
Journal:  N Engl J Med       Date:  2013-05-02       Impact factor: 91.245

Review 9.  Group A streptococcus and its antibiotic resistance.

Authors:  D Passàli; M Lauriello; G C Passàli; F M Passàli; L Bellussi
Journal:  Acta Otorhinolaryngol Ital       Date:  2007-02       Impact factor: 2.124

10.  Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network's PATCH II trial.

Authors:  Kim Thomas; Angela Crook; Katharine Foster; James Mason; Joanne Chalmers; John Bourke; Adam Ferguson; Nick Level; Andrew Nunn; Hywel Williams
Journal:  Br J Dermatol       Date:  2011-12-06       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.